The Centers for Medicare & Medicaid Services is accepting comments through Aug. 11 on whether to establish a national Medicare coverage policy for monoclonal antibodies to treat Alzheimer’s disease.

The Food and Drug Administration recently approved the first such drug (aducanumab) through an accelerated pathway that requires the company to verify clinical benefit in a post-approval trial. Medicare administrative contractors are currently making coverage determinations for aducanumab at the local level.

Stakeholders may register for CMS webinars July 22 to learn more or comment. CMS plans to release a proposed decision within six months and a final decision within nine months. 

Related News Articles

Headline
The Medicare Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2026, according to the latest annual report released Aug. 31…
Headline
The AHA Aug. 30 urged the Centers for Medicare & Medicaid Services to maintain a focus on accountable and innovative health care over the next decade and…
Headline
The Centers for Medicare & Medicaid Services today issued a Health Plan Management System memo to all Medicare Advantage Organizations and Medicare-…
Headline
President Biden today urged Congress to allow Medicare to negotiate prescription drug prices and cap the amount beneficiaries pay out-of-pocket for drugs each…
Headline
A new study published in JAMA Internal Medicine is confirming the role Medicare plays in decreasing disparities in health care access and coverage in the…
News
Reps. Peter Welch, D-Vt., Suzan DelBene, D-Wash., Darin LaHood, R-Ill., and Brad Wenstrup, R-Ohio, yesterday reintroduced the Value in Health Care Act, AHA-…